First targeted therapy for rare T-cell lymphoma after CAR T treatment successful

A team of researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has successfully treated a rare and aggressive T-cell lymphoma that developed after CAR T-cell therapy for multiple myeloma, marking a first in the field of hematologic cancer research. The findings were published in the New England Journal of Medicine.